Reduction of angiocidin contributes to decreased HepG2 cell proliferation

about

Non-communicable diseases are reaching epidemic proportions: evidence from low and middle income countries.

P2860

Q42912124-BFFD626A-E623-4241-8268-1F9DDB359C5A

P2860

Reduction of angiocidin contributes to decreased HepG2 cell proliferation

Item

http://www.wikidata.org/entity/Q37298953

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Reduction of angiocidin contributes to decreased HepG2 cell proliferation

@en

Reduction of angiocidin contributes to decreased HepG2 cell proliferation.

@nl

type

Item

label

Reduction of angiocidin contributes to decreased HepG2 cell proliferation

@en

Reduction of angiocidin contributes to decreased HepG2 cell proliferation.

@nl

prefLabel

Reduction of angiocidin contributes to decreased HepG2 cell proliferation

@en

Reduction of angiocidin contributes to decreased HepG2 cell proliferation.

@nl

P1476

Reduction of angiocidin contributes to decreased HepG2 cell proliferation

@en

P2093

D Tian

http://www.w3.org/2001/XMLSchema#string

H B Tong

http://www.w3.org/2001/XMLSchema#string

K Feng

http://www.w3.org/2001/XMLSchema#string

R Jian

http://www.w3.org/2001/XMLSchema#string

X G Guan

http://www.w3.org/2001/XMLSchema#string

X Q Guan

http://www.w3.org/2001/XMLSchema#string

X Sun

http://www.w3.org/2001/XMLSchema#string

P2860

The interaction of angiocidin with tissue transglutaminase

Cloning and characterization of angiocidin, a tumor cell binding protein for thrombospondin-1.

Angiocidin inhibits breast cancer proliferation through activation of epidermal growth factor receptor and nuclear factor kappa (NF-ĸB).

Treatment of hepatocellular carcinoma: is there an optimal strategy?

Clinical significance of serum angiocidin levels in hepatocellular carcinoma.

Identification and characterization of a tumor cell receptor for CSVTCG, a thrombospondin adhesive domain

Signaling pathways in hepatocellular carcinoma.

Histopathology and clinical assessment correlate with the cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) receptor of thrombospondin-1 in breast tumors.

The immunomodulatory role of angiocidin, a novel angiogenesis inhibitor.

Angiocidin inhibitory peptides decrease tumor burden in a murine colon cancer model.

P304

560-564

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4314/AHS.V13I3.5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258703681

http://www.w3.org/2001/XMLSchema#string

P698

24250289

http://www.w3.org/2001/XMLSchema#string

P932

3824429

http://www.w3.org/2001/XMLSchema#string

Reduction of angiocidin contributes to decreased HepG2 cell proliferation

about

P2860

P2860

Reduction of angiocidin contributes to decreased HepG2 cell proliferation

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932